Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Claire N Harrison, Professor, Jacqueline S Garcia, MD, Ruben A Mesa, MD, Tim CP Somervaille, MD PhD, Rami S. Komrokji, MD, Naveen Pemmaraju, MD, Catriona Jamieson, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, James M. Foran, MD, Casey L. O'Connell, MD, Leanne Holes, BS, MBA,, Jia Jia, PhD MBA, Jason Harb, PhD, Jessica Hutti, PhD, Josef T. Prchal, MD

Blood (2019) 134 (Supplement_1): 671.

https://doi.org/10.1182/blood-2019-130158

Published: 2019

Journal Articles

Iadademstat Shows Efficacy in Elderly AML Patients in Combination with Azacitidine. Alice Trial

Carlos Buesa, PhD, Tim CP Somervaille, MD PhD, Mabel Arevalo, PhD, Jordi Xaus, PhD, Sonia Gutierrez, Roger Bullock, MD

Blood (2019) 134 (Supplement_1): 3839.

https://doi.org/10.1182/blood-2019-125121

Published: 2019

Journal Articles

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

Tomasz Knurowski, PhD MD, Karen Clegg, PhD, Nigel Brooks, PhD, Fay Ashby, Neil A Pegg, PhD, William West, PhD, Harriet S Walter, Tim CP Somervaille, MD PhD, Steven Knapper, DM, Andrew Davies, MD PhD

Blood (2019) 134 (Supplement_1): 1266.

https://doi.org/10.1182/blood-2019-124797

Published: 2019

Journal Articles

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Nigel Brooks, PhD, Meera Raja, PhD, Barbara W Young, PhD, Gary J Spencer, PhD, Tim CP Somervaille, MD PhD, Neil A Pegg, PhD

Blood (2019) 134 (Supplement_1): 2560.

https://doi.org/10.1182/blood-2019-124707

Published: 2019

Journal Articles

Genome-Wide CRISPR-Cas9 Screen Identifies Sensitizers to LSD1 Inhibition in MLL-Translocated Human AML Cells

Gauri Deb, MS, PhD, Bettina Wingelhofer, PhD, Emma Williams, PhD, Hui-Sun Leong, PhD, Tim CP Somervaille, MD PhD

Blood (2018) 132 (Supplement 1): 178.

https://doi.org/10.1182/blood-2018-178

Published: 2018

NARROW

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Iadademstat Shows Efficacy in Elderly AML Patients in Combination with Azacitidine. Alice Trial

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Genome-Wide CRISPR-Cas9 Screen Identifies Sensitizers to LSD1 Inhibition in MLL-Translocated Human AML Cells

Email alerts

ASH Publications

American Society of Hematology

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Iadademstat Shows Efficacy in Elderly AML Patients in Combination with Azacitidine. Alice Trial

An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Genome-Wide CRISPR-Cas9 Screen Identifies Sensitizers to LSD1 Inhibition in MLL-Translocated Human AML Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only